Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2021-2031F

The global pharmacogenomics technology market is projected to expand significantly, from USD 6.87 billion in 2025 to USD 11.25 billion by 2031, demonstrating an 8.57% Compound Annual Growth Rate. This technology involves diagnostic tools, assay kits, and bioinformatics software used to analyze genetic variations impacting individual responses to drugs. Key growth drivers include the increasing global incidence of chronic diseases, which necessitate intricate medication plans, and a growing regulatory emphasis on using precision medicine to minimize adverse drug reactions. Additionally, pharmaceutical companies are integrating biomarker analysis into clinical trials to boost drug safety and effectiveness. Data from the Personalized Medicine Coalition indicates that personalized medicines constituted around 38% of new therapeutic molecular entities approved by the U.S. FDA in 2025, highlighting robust industry and regulatory support for these advancements.

However, despite these positive growth trajectories, the market encounters a substantial obstacle: the inconsistent reimbursement environment for genetic testing. The absence of uniform coverage policies across both private and public payers generates financial instability for healthcare providers, often discouraging the routine use of pharmacogenomic tests and hindering their wider clinical adoption.

Market Driver

The market is being significantly influenced by the increasing use of pharmacogenomics in oncology, where clinicians are more frequently employing genetic profiling to customize cancer therapies. This method enables the detection of specific tumor mutations and germline variants, which helps predict drug effectiveness, consequently reducing ineffective prescriptions and adverse toxicities. Pharmaceutical firms are actively incorporating these functionalities into their offerings to advance precision oncology solutions. For example, Exact Sciences Corp. reported $655 million in Precision Oncology revenue for the full year 2024, as noted in their February 2025 'Fourth Quarter and Full Year 2024 Results', underscoring the considerable commercial scope of these diagnostic tools. This trend is further amplified by the increasing need for patient stratification in clinical trials to ensure treatments align with the most responsive genetic profiles.

Simultaneously, progress in next-generation sequencing (NGS) and diagnostic technologies is making pharmacogenomics more accessible by substantially cutting costs and speeding up turnaround times. High-throughput sequencing platforms have evolved, making comprehensive genomic profiling viable for routine clinical applications, moving beyond solely specialized research. Frontline Genomics reported in March 2025 that Illumina stated in 2024 it could achieve whole genome sequencing for as little as $200 per genome, a development that improves the economic feasibility of large-scale population testing. This growth is also fueled by broader ecosystem support, as evidenced by the UK Government's July 2025 announcement of an investment of up to £600 million for an advanced health data platform integrating genomic and clinical data, thereby further embedding pharmacogenomic infrastructure into national healthcare systems.

Market Challenge

The inconsistent reimbursement framework for genetic testing poses a significant hurdle to the global pharmacogenomics technology market. When private and public payers lack standardized coverage policies, healthcare providers and diagnostic laboratories encounter considerable financial uncertainties. This unpredictable payment scenario frequently forces medical facilities to restrict the uptake of pharmacogenomic instruments and assay kits, as they cannot ensure revenue for these specialized services. Consequently, clinicians often become reluctant to routinely order these tests, effectively impeding the integration of precision medicine into standard patient care despite its established clinical advantages.

The severity of this financial impediment is highlighted by recent industry figures demonstrating the challenges in securing payments. The American Pharmacogenomics Association reported in 2025 that the total reimbursement rate for submitted pharmacogenomic testing claims was merely 46 percent. This statistic reveals that less than half of these diagnostic claims were paid, fostering an economically unsustainable environment for numerous laboratories. Such elevated denial rates directly deter investment in novel bioinformatics software and testing infrastructure, thereby limiting the market's wider commercial growth.

Market Trends

The market is being transformed by the integration of Artificial Intelligence and Machine Learning for genomic data interpretation, which addresses the challenges of analyzing extensive multi-omics datasets. In contrast to conventional manual methods that often struggle with polygenic risk scores, AI algorithms can swiftly pinpoint complex gene-drug interactions and forecast therapeutic outcomes with high accuracy. This capability resolves a bottleneck stemming from the rapid growth of genomic data. This technological advancement is crucial for clinical integration, as it improves the dependability of prescribing recommendations beyond conventional guidelines. A validation study of the AI tool Sherpa Rx, mentioned by the American Pharmacogenomics Association in December 2025's 'The Biggest Pharmacogenomics Advances of 2025 - Year in Review', demonstrated that the model achieved 90 percent accuracy in responding to intricate pharmacogenomic inquiries, significantly surpassing standard large language models.

Concurrently, the rise of preemptive pharmacogenomic screening models signals a strategic pivot from reactive testing towards a proactive, population-wide methodology. Healthcare systems are increasingly initiating pilot programs where patients undergo genotyping prior to needing medication, ensuring their genetic data is consistently accessible within electronic health records to inform subsequent prescribing choices. This approach is garnering significant public acceptance, which is vital for its widespread adoption beyond specialized oncology contexts. A survey by Queen Mary University of London, reported in The Pharmaceutical Journal in February 2025, found that 89 percent of respondents were amenable to pharmacogenomic testing to enhance drug efficacy and mitigate side effects.

Key Market Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Abbott Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Myriad Genetics, Inc.
• 23andMe Holding Co.
• Becton, Dickinson and Company

Report Scope

In this report, the Global Pharmacogenomics Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmacogenomics Technology Market, By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Pharmacogenomics Technology Market, By Technology

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Pharmacogenomics Technology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacogenomics Technology Market.

Available Customizations:

Global Pharmacogenomics Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).